Source:
In conclusion, Mogar et al [4] reaffirm the known IGF-1–lowering effect of clomiphene, which may be beneficial in men with hypogonadism and acromegaly, but raises important questions about clinical consequences in patients with unrecognized or untreated GHD. Current clinical and preclinical data do not support adverse effects of clomiphene on weight, body composition, glucose metabolism, and bone health; therefore, reduction of IGF-1 levels by clomiphene may not have the same clinical consequences as GHD. However, patients with structural pituitary disease and hypopituitarism treated with clomiphene require further study. Measurement of IGF-1 and testing for GHD may be justified in those who exhibit signs and symptoms of GHD on clomiphene or may also be considered in men prior to initiation of clomiphene. Additionally, further research is needed to see if patients treated for GHD would require GH dose adjustment.
Clomiphene Citrate, Hypogonadism, and IGF-1: An Analysis of Monitoring Recommendations
Executive Summary
This document synthesizes a commentary on the use of clomiphene citrate (CC) for male hypogonadism and its documented effect of lowering Insulin-like Growth Factor-1 (IGF-1) levels. A recent retrospective study by Mogar and colleagues has reignited this discussion by showing that CC treatment can lead to significant IGF-1 decreases, including drops of more than 2.0 standard deviations in some patients, prompting a recommendation for routine IGF-1 monitoring.
However, the commentary argues against the universal application of this recommendation, presenting several critical caveats. First, IGF-1 measurements are subject to significant intraindividual (10-30%) and interlaboratory (6.9-19%) variability, complicating the interpretation of changes. Second, and more crucially, a reduction in IGF-1 levels may not equate to the clinical manifestations of Growth Hormone Deficiency (GHD). Evidence suggests that clomiphene's direct and indirect effects may be beneficial for metabolism and bone health, potentially counterbalancing any negative consequences of lower IGF-1.
The commentary concludes that while CC's IGF-1 lowering effect is well-established, current data do not support adverse effects on weight, glucose metabolism, or bone health. Therefore, routine IGF-1 monitoring for all men on clomiphene is likely unnecessary. Instead, testing for GHD and measuring IGF-1 may be justified for specific patient groups, such as those with structural pituitary disease or those who develop GHD symptoms while on therapy. Further research is essential to understand the long-term clinical impact of CC-induced IGF-1 reduction and to determine if GH dose adjustments are needed for patients with pre-existing GHD.
The Dual Mechanism of Selective Estrogen Receptor Modulators (SERMs)
Selective Estrogen Receptor Modulators (SERMs), such as clomiphene citrate and tamoxifen, exhibit a complex dual-action mechanism that makes them relevant for treating both acromegaly and hypogonadism.
• Hepatic Action (IGF-1 Reduction): SERMs exert an estrogen-like effect in the liver. They activate the estrogen receptor, which in turn downregulates the JAK-STAT signaling pathway for growth hormone (GH). This process reduces the hepatic production of IGF-1, an effect that has led to the experimental use of SERMs in treating acromegaly.
• Pituitary-Hypothalamic Action (Testosterone Increase): At the pituitary-hypothalamic level, SERMs act as estrogen receptor blockers. This action stimulates the release of gonadotropins, which leads to ovulation in women and increased testosterone production in men. This mechanism is the basis for clomiphene's off-label use in treating male hypogonadism.
Evidence of SERM-Induced IGF-1 Reduction
The capacity of SERMs to lower IGF-1 levels is documented across various patient populations and is not limited to individuals with GH disorders.
General Findings and Acromegaly Studies
Multiple studies have quantified the IGF-1 lowering effect of different SERMs.
• Meta-Analysis in Acromegaly: A meta-analysis of observational studies involving 63 patients found a significant decrease in IGF-1 levels among postmenopausal women (n=49) with acromegaly treated with estradiol, tamoxifen, or raloxifene. However, the IGF-1 reduction in men (n=14) receiving SERMs for up to two months was not statistically significant.
• Prospective Trial in Acromegaly: An open-label trial evaluated clomiphene (50 mg/day) as an add-on therapy for 16 men with uncontrolled acromegaly and low testosterone. The results showed a 41% decrease in IGF-1 levels, with normalization achieved in 7 patients (44%). Concurrently, testosterone levels rose by 209%, normalizing in 4 patients (67%).
The Mogar et al. Study on Male Hypogonadism
A recent retrospective study by Mogar and colleagues provided "real-world" data that catalyzed the current discussion on IGF-1 monitoring.
• Study Design: The study reviewed 20 men with central hypogonadism (15 with structural pituitary disease, 5 idiopathic) treated with clomiphene citrate (50 mg thrice weekly for ≥3 months).
• Key Findings:
◦ Total testosterone levels increased in all patients.
◦ IGF-1 levels changed by a median of -0.60 standard deviations (SDs) in 15 participants (75%).
◦ Notably, two patients experienced a decrease in IGF-1 of more than 2.0 SDs.
• Conclusion: Based on these findings, the authors suggested that some hypogonadal men treated with clomiphene may develop low IGF-1 levels and therefore recommended IGF-1 monitoring for this patient population.
Counterarguments to Routine IGF-1 Monitoring
The commentary posits that the recommendation for routine monitoring may be premature, highlighting significant limitations in interpreting IGF-1 levels and a lack of evidence for negative clinical outcomes.
1. Analytical and Biological Variability of IGF-1 Assays
The reliability of a single IGF-1 measurement is challenged by inherent variability.
• Intraindividual Variability: IGF-1 levels can fluctuate by 10% to 30% on a week-to-week basis in the same person. This is driven by physiological factors such as protein intake, intercurrent illness, exercise, stress, and circadian rhythm.
• Interlaboratory Variability: Significant variability exists between different laboratories, reported to range from 6.9% to 19%. This is due to differences in immunoassays, mass spectrometry methods, local versus central calibration, and agreement on reagents. This makes it difficult to compare values over time if tests are not performed at the same facility.
2. Unclear Clinical Significance of Reduced IGF-1
A key argument is that a decline in the biochemical marker (IGF-1) may not translate to the clinical symptoms of GHD. The beneficial effects of clomiphene, both direct and secondary to testosterone increase, could potentially offset or mask the consequences of a lower IGF-1 level.
• Metabolism and Body Composition:
◦ Preclinical Data: In mice, clomiphene was found to induce the browning of white adipose tissue and reduce fat mass, though this has not been replicated in humans.
◦ Human Trial: A randomized, double-blind, placebo-controlled trial of obese men with functional hypogonadism and dysmetabolism showed that three months of clomiphene (25 mg daily) led to a significant reduction in fasting glucose, insulin, and insulin resistance. A trend toward reduced body mass index and waist circumference was also observed.
◦ PCOS Study: In women with PCOS, fasting insulin and insulin resistance remained stable despite significant reductions in IGF-1 during ovulation induction with clomiphene.
• Bone Health:
◦ The effects of clomiphene on bone appear to be positive, driven by its bone-selective estrogen agonist activity.
◦ Animal Models: Studies have shown clomiphene prevents bone loss.
◦ Retrospective Human Study: In hypogonadal men treated for at least 12 months, clomiphene led to significant improvements in mean femoral neck and lumbar spine bone density scores, in parallel with rising testosterone. This suggests a combined benefit from direct estrogen-like activity and increased sex steroids.
Unresolved Questions and Future Directives
The commentary concludes by outlining critical areas where further research is needed before clinical guidelines can be established.
• Mechanism of IGF-1 Reduction: The Mogar et al. study found no statistically significant correlation between the increase in free testosterone and the decrease in IGF-1. This suggests that the direct action of clomiphene on hepatic estrogen receptors may be more significant than the effect of testosterone aromatization to estrogen. However, estrogen levels were not measured, and further research is needed to clarify this mechanism.
• Long-Term Clinical Impact: The clinical repercussions of a persistent IGF-1 decrease induced by clomiphene are unknown.
• High-Risk Patient Populations: Patients with structural pituitary disease and hypopituitarism require dedicated study to assess the risks and benefits of clomiphene therapy.
• Interaction with GH Replacement: It is unknown if patients already receiving treatment for GHD would require an adjustment in their GH dose if they begin taking clomiphene.
Conclusion and Proposed Clinical Approach
The analysis indicates that while clomiphene citrate reliably lowers IGF-1 levels, this reduction may not carry the same clinical consequences as GHD. The available clinical and preclinical data do not support adverse effects on weight, body composition, glucose metabolism, or bone health; in fact, they often suggest a beneficial impact.
Based on this evidence, a nuanced approach to monitoring is proposed:
1. Routine Monitoring Not Justified: Universal, routine monitoring of IGF-1 levels in all men treated with clomiphene for hypogonadism is not supported by current evidence.
2. Targeted Monitoring is Warranted: IGF-1 measurement and testing for GHD may be justified in specific clinical scenarios:
◦ In patients who exhibit new signs and symptoms suggestive of GHD while on clomiphene therapy.
◦ Consideration may be given to baseline testing in men with known structural pituitary disease or hypopituitarism prior to initiating clomiphene.
In conclusion, Mogar et al [4] reaffirm the known IGF-1–lowering effect of clomiphene, which may be beneficial in men with hypogonadism and acromegaly, but raises important questions about clinical consequences in patients with unrecognized or untreated GHD. Current clinical and preclinical data do not support adverse effects of clomiphene on weight, body composition, glucose metabolism, and bone health; therefore, reduction of IGF-1 levels by clomiphene may not have the same clinical consequences as GHD. However, patients with structural pituitary disease and hypopituitarism treated with clomiphene require further study. Measurement of IGF-1 and testing for GHD may be justified in those who exhibit signs and symptoms of GHD on clomiphene or may also be considered in men prior to initiation of clomiphene. Additionally, further research is needed to see if patients treated for GHD would require GH dose adjustment.
Clomiphene Citrate, Hypogonadism, and IGF-1: An Analysis of Monitoring Recommendations
Executive Summary
This document synthesizes a commentary on the use of clomiphene citrate (CC) for male hypogonadism and its documented effect of lowering Insulin-like Growth Factor-1 (IGF-1) levels. A recent retrospective study by Mogar and colleagues has reignited this discussion by showing that CC treatment can lead to significant IGF-1 decreases, including drops of more than 2.0 standard deviations in some patients, prompting a recommendation for routine IGF-1 monitoring.
However, the commentary argues against the universal application of this recommendation, presenting several critical caveats. First, IGF-1 measurements are subject to significant intraindividual (10-30%) and interlaboratory (6.9-19%) variability, complicating the interpretation of changes. Second, and more crucially, a reduction in IGF-1 levels may not equate to the clinical manifestations of Growth Hormone Deficiency (GHD). Evidence suggests that clomiphene's direct and indirect effects may be beneficial for metabolism and bone health, potentially counterbalancing any negative consequences of lower IGF-1.
The commentary concludes that while CC's IGF-1 lowering effect is well-established, current data do not support adverse effects on weight, glucose metabolism, or bone health. Therefore, routine IGF-1 monitoring for all men on clomiphene is likely unnecessary. Instead, testing for GHD and measuring IGF-1 may be justified for specific patient groups, such as those with structural pituitary disease or those who develop GHD symptoms while on therapy. Further research is essential to understand the long-term clinical impact of CC-induced IGF-1 reduction and to determine if GH dose adjustments are needed for patients with pre-existing GHD.
The Dual Mechanism of Selective Estrogen Receptor Modulators (SERMs)
Selective Estrogen Receptor Modulators (SERMs), such as clomiphene citrate and tamoxifen, exhibit a complex dual-action mechanism that makes them relevant for treating both acromegaly and hypogonadism.
• Hepatic Action (IGF-1 Reduction): SERMs exert an estrogen-like effect in the liver. They activate the estrogen receptor, which in turn downregulates the JAK-STAT signaling pathway for growth hormone (GH). This process reduces the hepatic production of IGF-1, an effect that has led to the experimental use of SERMs in treating acromegaly.
• Pituitary-Hypothalamic Action (Testosterone Increase): At the pituitary-hypothalamic level, SERMs act as estrogen receptor blockers. This action stimulates the release of gonadotropins, which leads to ovulation in women and increased testosterone production in men. This mechanism is the basis for clomiphene's off-label use in treating male hypogonadism.
Evidence of SERM-Induced IGF-1 Reduction
The capacity of SERMs to lower IGF-1 levels is documented across various patient populations and is not limited to individuals with GH disorders.
General Findings and Acromegaly Studies
Multiple studies have quantified the IGF-1 lowering effect of different SERMs.
| Drug | Patient Population | Reported IGF-1 Reduction | Source |
| Tamoxifen | Women with breast cancer | 17% to 38% | [2] |
| Tamoxifen | Normal men | 25% | [2] |
| Clomiphene Citrate | Women with Polycystic Ovary Syndrome (PCOS) | 32% to 35% | [2] |
| Clomiphene Citrate | Controls | Approximately 20% | [2] |
• Meta-Analysis in Acromegaly: A meta-analysis of observational studies involving 63 patients found a significant decrease in IGF-1 levels among postmenopausal women (n=49) with acromegaly treated with estradiol, tamoxifen, or raloxifene. However, the IGF-1 reduction in men (n=14) receiving SERMs for up to two months was not statistically significant.
• Prospective Trial in Acromegaly: An open-label trial evaluated clomiphene (50 mg/day) as an add-on therapy for 16 men with uncontrolled acromegaly and low testosterone. The results showed a 41% decrease in IGF-1 levels, with normalization achieved in 7 patients (44%). Concurrently, testosterone levels rose by 209%, normalizing in 4 patients (67%).
The Mogar et al. Study on Male Hypogonadism
A recent retrospective study by Mogar and colleagues provided "real-world" data that catalyzed the current discussion on IGF-1 monitoring.
• Study Design: The study reviewed 20 men with central hypogonadism (15 with structural pituitary disease, 5 idiopathic) treated with clomiphene citrate (50 mg thrice weekly for ≥3 months).
• Key Findings:
◦ Total testosterone levels increased in all patients.
◦ IGF-1 levels changed by a median of -0.60 standard deviations (SDs) in 15 participants (75%).
◦ Notably, two patients experienced a decrease in IGF-1 of more than 2.0 SDs.
• Conclusion: Based on these findings, the authors suggested that some hypogonadal men treated with clomiphene may develop low IGF-1 levels and therefore recommended IGF-1 monitoring for this patient population.
Counterarguments to Routine IGF-1 Monitoring
The commentary posits that the recommendation for routine monitoring may be premature, highlighting significant limitations in interpreting IGF-1 levels and a lack of evidence for negative clinical outcomes.
1. Analytical and Biological Variability of IGF-1 Assays
The reliability of a single IGF-1 measurement is challenged by inherent variability.
• Intraindividual Variability: IGF-1 levels can fluctuate by 10% to 30% on a week-to-week basis in the same person. This is driven by physiological factors such as protein intake, intercurrent illness, exercise, stress, and circadian rhythm.
• Interlaboratory Variability: Significant variability exists between different laboratories, reported to range from 6.9% to 19%. This is due to differences in immunoassays, mass spectrometry methods, local versus central calibration, and agreement on reagents. This makes it difficult to compare values over time if tests are not performed at the same facility.
2. Unclear Clinical Significance of Reduced IGF-1
A key argument is that a decline in the biochemical marker (IGF-1) may not translate to the clinical symptoms of GHD. The beneficial effects of clomiphene, both direct and secondary to testosterone increase, could potentially offset or mask the consequences of a lower IGF-1 level.
• Metabolism and Body Composition:
◦ Preclinical Data: In mice, clomiphene was found to induce the browning of white adipose tissue and reduce fat mass, though this has not been replicated in humans.
◦ Human Trial: A randomized, double-blind, placebo-controlled trial of obese men with functional hypogonadism and dysmetabolism showed that three months of clomiphene (25 mg daily) led to a significant reduction in fasting glucose, insulin, and insulin resistance. A trend toward reduced body mass index and waist circumference was also observed.
◦ PCOS Study: In women with PCOS, fasting insulin and insulin resistance remained stable despite significant reductions in IGF-1 during ovulation induction with clomiphene.
• Bone Health:
◦ The effects of clomiphene on bone appear to be positive, driven by its bone-selective estrogen agonist activity.
◦ Animal Models: Studies have shown clomiphene prevents bone loss.
◦ Retrospective Human Study: In hypogonadal men treated for at least 12 months, clomiphene led to significant improvements in mean femoral neck and lumbar spine bone density scores, in parallel with rising testosterone. This suggests a combined benefit from direct estrogen-like activity and increased sex steroids.
Unresolved Questions and Future Directives
The commentary concludes by outlining critical areas where further research is needed before clinical guidelines can be established.
• Mechanism of IGF-1 Reduction: The Mogar et al. study found no statistically significant correlation between the increase in free testosterone and the decrease in IGF-1. This suggests that the direct action of clomiphene on hepatic estrogen receptors may be more significant than the effect of testosterone aromatization to estrogen. However, estrogen levels were not measured, and further research is needed to clarify this mechanism.
• Long-Term Clinical Impact: The clinical repercussions of a persistent IGF-1 decrease induced by clomiphene are unknown.
• High-Risk Patient Populations: Patients with structural pituitary disease and hypopituitarism require dedicated study to assess the risks and benefits of clomiphene therapy.
• Interaction with GH Replacement: It is unknown if patients already receiving treatment for GHD would require an adjustment in their GH dose if they begin taking clomiphene.
Conclusion and Proposed Clinical Approach
The analysis indicates that while clomiphene citrate reliably lowers IGF-1 levels, this reduction may not carry the same clinical consequences as GHD. The available clinical and preclinical data do not support adverse effects on weight, body composition, glucose metabolism, or bone health; in fact, they often suggest a beneficial impact.
Based on this evidence, a nuanced approach to monitoring is proposed:
1. Routine Monitoring Not Justified: Universal, routine monitoring of IGF-1 levels in all men treated with clomiphene for hypogonadism is not supported by current evidence.
2. Targeted Monitoring is Warranted: IGF-1 measurement and testing for GHD may be justified in specific clinical scenarios:
◦ In patients who exhibit new signs and symptoms suggestive of GHD while on clomiphene therapy.
◦ Consideration may be given to baseline testing in men with known structural pituitary disease or hypopituitarism prior to initiating clomiphene.
Last edited by a moderator:
